Advanced search

Instruments

Name		Stock exchange	Average volume	Price	Type
TIMOTHY PLAN MARKET NEUTRAL ETF - USD	TPMN	Nyse	14,693	23.94 USD	ETF
TIMOTHY PLAN HIGH DIVIDEND STOCK ENHANCED ETF - USD	TPHE	Nyse	6,540	24.63 USD	ETF
TIMOTHY PLAN US LARGE/MID CAP CORE ENHANCED ETF - USD	TPLE	Nyse	3,241	24.81 USD	ETF

News (336)

Horizon Therapeutics Public Limited Company Announces the Cessation of Member of the Board of Directors	07/23/07	CI
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)	02/23/02	BU
MIRUM PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K)	06/23/06	AQ
Mirum Pharmaceuticals, Inc. Announces Board Changes	06/23/06	CI
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)	06/23/06	BU
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)	04/23/04	BU
Form 8.1 Opening Position Disclosure (Horizon Therapeutics plc)	13/22/13	BU
HORIZON THERAPEUTICS PUBLIC LTD CO : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	12/22/12	AQ
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc	12/22/12	BU
Century Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates	10/22/10	GL
Century Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates	10/22/10	GL
CENTURY THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)	03/22/03	AQ
Century Therapeutics Announces Appointment of Daphne Quimi and Timothy Walbert to its Board of Directors	03/22/03	GL
Century Therapeutics Announces Appointment of Daphne Quimi and Timothy Walbert to its Board of Directors	03/22/03	GL
Century Therapeutics, Inc. Announces Board Changes	03/22/03	CI
AURINIA PHARMACEUTICALS INC. : Regulation FD Disclosure, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	20/22/20	AQ
AURINIA PHARMACEUTICALS INC. : Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	21/22/21	AQ
Transcript : Aurinia Pharmaceuticals Inc. - Shareholder/Analyst Call	17/22/17
EXICURE, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	17/22/17	AQ
EXICURE, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	26/22/26	AQ
Exicure, Inc. Announces Leadership Transition and Changes to the Board of Directors	07/22/07	AQ
Exicure : Announces Leadership Transition and Changes to the Board of Directors - Form 8-K	04/22/04	PU
EXICURE, INC. : Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	04/22/04	AQ
Exicure, Inc. Announces Leadership Transition and Changes to the Board of Directors	04/22/04	BU
Exicure, Inc. Announces Executive, Board and Committee Changes	04/22/04	CI
AURINIA PHARMACEUTICALS INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	11/21/11	AQ
Aurinia Pharmaceuticals : Announces Results of the 2021 Annual General Meeting	08/21/08	BU
Transcript : Aurinia Pharmaceuticals Inc. - Shareholder/Analyst Call	07/21/07
Transcript : Exicure, Inc. - Shareholder/Analyst Call	01/21/01
VIELA BIO, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	15/21/15	AQ
Viela Bio, Inc. Announces Board Changes	15/21/15	CI
Exicure, Inc. : Reports Full Year 2020 Financial Results and Corporate Progress	11/21/11	BU
Exicure : Announces Appointments of Elizabeth Garofalo, M.D., and Andrew Sassine to Its Board of Directors	09/21/09	BU
Exicure : Announces Appointment of James Sulat to Board of Directors	05/21/05	BU
ASSERTIO HOLDINGS, INC. : Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	15/20/15	AQ
Assertio Holdings, Inc. Announces Executive Changes	15/20/15	CI
Global Genes : Honors Leaders, Advocates, and Innovators in Rare Disease From Around the World at the 2020 RARE Champion of Hope Celebration	17/20/17	BU
Perspectives/IIT Math and Science Academy Calls on Chicago Companies to Meaningfully Engage with Schools to Help Close Technology and Access Gaps in Education	14/20/14	BU
Aurinia Pharmaceuticals : Reports Second Quarter 2020 Financial Results and Recent Operational Highlights	12/20/12	BU
Aurinia Pharmaceuticals : Announces Results of Annual General Meeting	03/20/03	BU
ASSERTIO HOLDINGS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Change in Directors or Principal Officers, Amendment or Waiver to Code of Ethics, Financial Statements and Exhibits (form 8-K)	28/20/28	AQ
ZYLA LIFE SCIENCES : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements (form 8-K)	21/20/21	AQ
Assertio : Completed Merger with Zyla Life Sciences	20/20/20	PR
Assertio and Zyla Life Sciences Announces Board Appointments to Combined Company	20/20/20	CI
Assertio Therapeutics, Inc. completed the acquisition of Zyla Life Sciences.	20/20/20	CI

1234NextSee all

Insiders

Timothy Walbert

Timothy P. Walbert is a businessperson who has been the head of 10 different companies and presently is Chairman, President & Chief Executive Officer of Horizon Therapeutics Plc, President & Chief Executive Officer of Horizon Therapeutics USA, Inc. (a subsidiary of Horizon Therapeutics Plc), Co-Chairman for MATTER Chicago, Chairman of Exicure, Inc. and President & Director at Viela Bio, Inc. He is also Member of The National Organization for Rare Disorders, Inc. and Member of Illinois Innovation Council and on the board of 9 other companies. In the past Mr. Walbert was Divisional VP & General Manager-Immunology at Abbott Laboratories, Manager-Market Integration at Merck & Co., Inc., Chairman for Zyla Life Sciences, Chairman, President & Chief Executive Officer for Horizon Pharma, Inc., President & Chief Executive Officer at Hyperion Therapeutics, Inc., President, Chief Executive Officer & Director at IDM Pharma, Inc., President & Chief Executive Officer for Horizon Therapeutics, Inc., Territory Manager at Wyeth Corp., Executive Vice President-Commercial Operations at NeoPharm, Inc. and Product Manager-Arthrotec & Cytotec at G.D. Searle & Co., Inc. Mr. Walbert received an undergraduate degree from Muhlenberg College.

Mark Walbert worked as a Project Manager at PULS GmbH in 2017.

James N. Walbert

Andreas Walbert

Andreas Walbert worked as an Equity Hedge Fund Analyst at Goldman Sachs Asset Management International from 2012 to 2017.
He then worked as a Portfolio Manager at Citadel Europe LLP.
Later, he worked as a Research Analyst at Millennium Capital Partners LLP from 2017 to 2019.

No results for this search